Gumprecht 2011.

Methods	6‐Week to 8‐week wash‐out dietary stabilisation period 4‐Week before‐and‐after study
Participants	Eligible individuals aged 18 to 73 years; type 2 diabetes and combined dyslipidaemia, LDL‐C ≥ 100 and ≤ 220 mg/dL (≥ 2.6 and ≤ 5.7 mmol/L), TG ≥ 150 mg/dL (≥ 1.7 mmol/L) Exclusion criteria: homozygous FH, secondary dyslipidaemia, significant cardiovascular and cerebrovascular disease, neoplastic disease within 10 years, SBP/DBP > 160/90 mmHg, muscular or neuromuscular disease, supplement use that affects lipid metabolism Atorvastatin baseline LDL‐C: 3.77 mmol/L (146 mg/dL)
Interventions	Atorvastatin 20 mg/d Pitavastatin 4 mg/d
Outcomes	Per cent change from baseline at 4 weeks of serum LDL‐C
Notes	Atorvastatin group was analysed       SD was imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 20 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Data on all participants were reported
Selective reporting (reporting bias)	High risk	Only LDL‐C was measured
Other bias	Unclear risk	The study was funded by Kowa Research Europe Ltd